Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Xeris Biopharma Holdings Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
XERS
Nasdaq
8731
https://www.xerispharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Xeris Biopharma Holdings Inc
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
- Apr 17th, 2024 11:24 am
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions
- Apr 5th, 2024 3:15 pm
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Apr 3rd, 2024 8:05 pm
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Apr 2nd, 2024 11:00 am
Here's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Results
- Mar 9th, 2024 2:14 pm
Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023
- Mar 7th, 2024 6:47 pm
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript
- Mar 7th, 2024 4:56 pm
Q4 2023 Xeris Biopharma Holdings Inc Earnings Call
- Mar 7th, 2024 4:16 am
Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates
- Mar 6th, 2024 1:15 pm
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
- Mar 6th, 2024 12:02 pm
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
- Mar 6th, 2024 12:00 pm
Why Xeris (XERS) Might Surprise This Earnings Season
- Mar 5th, 2024 2:42 pm
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
- Feb 28th, 2024 12:00 pm
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
- Feb 5th, 2024 12:00 pm
Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza
- Jan 11th, 2024 1:30 pm
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
- Jan 10th, 2024 1:00 pm
7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024
- Jan 8th, 2024 7:48 pm
Xeris Biopharma Updates Its Outlook for 2023
- Jan 4th, 2024 12:00 pm
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Dec 27th, 2023 12:00 pm
11 High Growth Micro-Cap Stocks to Buy
- Dec 24th, 2023 12:32 am
Scroll